semaglutide .75 7.2mg achieved 20.7% weight loss in STEP UP obesity trial Wegovy (semaglutide) Injector 1.7 mg/0.75 mL Ozempic (Semaglutide Injection) 2 mg

"Weight management is multifactorial and involves genetics, hormones, mental health, diet, physical activity and social factors." While Wegovy is currently the big player in the field in New Zealand, "There are other medications or treatments available and more medications are expected to be available soon," she said

Simple remedies like probiotics, herbal teas, and light exercise may also help improve digestion

Maintenance Dosing: Once the desired therapeutic effect is achieved, a maintenance dose is established

These are not interchangeable programs, and patients often conflate the two based on media coverage

Development timeline : Survodutide Phase 3 results are expected sooner (H1 2026 for obesity), potentially reaching market before retatrutide